S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:VACC

Vaccitech (VACC) Stock Price, News & Analysis

$2.33
-0.07 (-2.92%)
(As of 03/27/2024 ET)
Today's Range
$2.31
$2.40
50-Day Range
$2.33
$5.00
52-Week Range
$1.64
$5.10
Volume
30,871 shs
Average Volume
244,643 shs
Market Capitalization
$89.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.63

Vaccitech MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
227.3% Upside
$7.63 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.41) to ($2.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.52 out of 5 stars

Medical Sector

886th out of 939 stocks

Pharmaceutical Preparations Industry

408th out of 435 stocks

VACC stock logo

About Vaccitech Stock (NASDAQ:VACC)

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

VACC Stock Price History

VACC Stock News Headlines

Vaccitech (NASDAQ:VACC) Trading 7% Higher
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Barinthus Biotherapeutics plc (BRNS)
Barinthus Biotherapeutics Plc. - ADR
SIRI, EC and PBTS among pre-market losers
Morgan Stanley Downgrades Vaccitech
Vaccitech surges despite Morgan Stanley downgrade
Health Care Up on Defensive Bets -- Health Care Roundup
See More Headlines
Receive VACC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VACC
Fax
N/A
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.63
High Stock Price Target
$12.00
Low Stock Price Target
$3.25
Potential Upside/Downside
+227.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$5.34 million
Net Margins
-409.18%
Pretax Margin
-442.00%

Debt

Sales & Book Value

Annual Sales
$13.42 million
Cash Flow
$0.12 per share
Book Value
$6.52 per share

Miscellaneous

Free Float
36,234,000
Market Cap
$89.81 million
Optionable
Not Optionable
Beta
-0.40
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. William J. Enright MBA (Age 60)
    CEO & Director
    Comp: $916.62k
  • Ms. Sarah Gilbert
    Co-Founder
  • Mr. Adrian Hill Ph.D.
    Co-Founder & Scientific Advisor
  • Ms. Gemma Brown (Age 33)
    CFO & Company Secretary
  • Mr. Chris Ellis (Age 63)
    Chief Operating Officer
  • Dr. Nadege Pelletier Ph.D. (Age 45)
    Chief Scientific Officer
  • Mr. Graham GriffithsMr. Graham Griffiths (Age 44)
    Chief Business Officer
  • Ms. Elizabeth Eagling-Vose M.B.A.
    Head of Clinical Operations
  • Bernie McDonald
    Head of IP
  • Geoffrey Lynn
    Senior Vice President of Synthetic Immunotherapies

VACC Stock Analysis - Frequently Asked Questions

Should I buy or sell Vaccitech stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VACC shares.
View VACC analyst ratings
or view top-rated stocks.

What is Vaccitech's stock price target for 2024?

2 equities research analysts have issued 1 year price targets for Vaccitech's shares. Their VACC share price targets range from $3.25 to $12.00. On average, they predict the company's share price to reach $7.63 in the next year. This suggests a possible upside of 227.3% from the stock's current price.
View analysts price targets for VACC
or view top-rated stocks among Wall Street analysts.

How have VACC shares performed in 2024?

Vaccitech's stock was trading at $3.69 at the beginning of the year. Since then, VACC shares have decreased by 36.9% and is now trading at $2.33.
View the best growth stocks for 2024 here
.

How were Vaccitech's earnings last quarter?

Vaccitech plc (NASDAQ:VACC) issued its quarterly earnings data on Friday, November, 12th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.25. The company earned $0.02 million during the quarter, compared to the consensus estimate of $1.65 million. Vaccitech had a negative net margin of 409.18% and a negative trailing twelve-month return on equity of 23.41%.

When did Vaccitech IPO?

Vaccitech (VACC) raised $110 million in an IPO on Friday, April 30th 2021. The company issued 6,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

Who are Vaccitech's major shareholders?

Vaccitech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Ipswich Investment Management Co. Inc. (0.06%). Insiders that own company stock include Christopher Ellis, Graham Griffiths, Joseph Scheeren, Karen A Dawes, M&G Investment Management Ltd, Robin Wright, Sciences Innovation Plc Oxford and William Enright.
View institutional ownership trends
.

How do I buy shares of Vaccitech?

Shares of VACC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VACC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners